Gabapentin Enacarbil Extended-Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial.

Eugene M LaskaCarole E SiegelZiqiang LinMichael BogenschutzCharles R Marmar

Published in: Alcoholism, clinical and experimental research (2020)

There are substantial causal benefits of treatment with GE-XR for a subset of patients predicted to be likely responders. The likely responder statistical paradigm is a promising approach for analyzing randomized clinical trials to advance personalized treatment.

Keyphrases

newly diagnosed
ejection fraction
randomized controlled trial
spinal cord injury
patient reported outcomes
combination therapy